Vancouver, British Columbia, December 6, 2023 – Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a leading biotechnology company specializing in the development of novel treatments for neuropsychiatric disorders, epilepsy, and pain, is excited to announce a fully management-subscribed, non-brokered private placement. This placement involves up to 661,765 units of…
– – BMB-101 is ahighly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders. – – qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascending Dose arm of the study. – – Proof of Mechanism…
BMB-101 is ahighly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsiesand other indications, such as psychosis, addiction, and impulse control disorders BMB-101 demonstrated an excellent safety and tolerability profile in single ascending dose, multiple ascending dose and food effects study BMB-101 demonstrated central target engagement and predictable plasma pharmacokinetics …
Vancouver, British Columbia, July 11, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain,announces that, further to its news release on June 22, 2023, the Company will consolidate its common shares (the “CommonShares”)…
Vancouver, British Columbia, June22, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain,announces thatit intends to consolidate its common shares (the “Common shares”) on a five (5) to one (1) basis (the “Consolidation”).…
— BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B – — BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT2A and 5-HT2A/2C agonists inspired from natural compound scaffolds – Vancouver, British Columbia, April 19, 2023…
— Presentation entitled “BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility” – — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — Vancouver, British Columbia, April 10, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel…
— First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway inAustralia — — Company has transitioned from a discovery to a development organization – — Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 — – Vancouver, British Columbia, February 27, 2023 – Bright Minds…
— David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare diseases — Vancouver, British Columbia, February 17, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of…
Vancouver, British Columbia, February 8, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a letter (the “Deficiency Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated February 2, 2023, stating that following the resignation of Dr. Williamson from the Company’s board of directors and audit…
×
"*" indicates required fields